Healthcare Executive Mandy Transcript Chinese
GSI TympStar 产品说明书
P.O. BOX 44994 •MADISON WI 53744.4994 •PHONE: +1.608.441.2323 •TOLL FREE: 800.700.2282GRASON-STADLER NICOLET BIOMEDICAL NICOLET VASCULAR TOENNIESPRODUCT SPECIFICATIONS November 2004 | GSI TympStar | 2000-0112 Rev1The following specifications apply to both Version 1and Version 2 of the GSI TympStar. > Bold arrowed type indicates the additional capabilities of Version 2.GENERAL SPECIFICATIONS W x D x H: 52 cm x 38 cm x 32 cm Weight: 7.5 Kg Shipping Weight: 13.4 Kg Power Consumption: 120 Watts maximum Test Types: Tympanometry, Acoustic Reflex Threshold,Reflex Decay, Eustachian T ube Function (Intact & Perforated )Protocols: Diagnostic, Screening, User-defined > Special Tests: Two-component T ympanometry,Multiple Frequency T ympanometry, Acoustic Reflex Latency Test, Reflex Sensitization Display: Internal or External VGA Monitor Interface: RS232, parallel and keyboard output Printout: Internal or External Deskjet or Laserjet Printer PROBE TONE 226 Hz (85 dB SPL ±1.5 dB)> 678 Hz (85 dB SPL ±3.0 dB)> 1000 Hz (75 dB SPL ±3.0 dB)Accuracy: ±1%Harmonic Distortion: Less than 5%ADMITTANCE MEASUREMENTS Range: 226 Hz (-1.0 to +7.0)> 678 Hz (-5.0 to +25)> 1000 Hz (-5.0 to +30)Sensitivity Scale: Auto Scales to Appropriate Range,Manual selection also possible in Reflex Modes only Accuracy (226 Hz): Tymp Mode: ±5% of reading or ±0.1 ml, whichever is greater Reflex Mode: ±5% of reading or ±0.2 ml, whichever is greater PRESSURE MEASUREMENTS (load volume of 0.2 to 7.0 ml)Range:Normal = +200 to -400 daPa Wide = +400 to -600 daPa Accuracy: ±10% of reading or ±10 daPa, whichever is greater Sweep Rate: 12.5, 50.0 and 600/200 daPa/sec, > 200 daPa/sec.Sweep Accuracy: 10% of nominal rate Maximum limits (in 0.5cc cavity ): -800 daPa & +600 daPa REFLEX MEASUREMENTS Stimuli: > 250, 500, 1k, 2k, 4k, BBN, LBN, HBN,> Click (100 microseconds pulse), External Input,Non-acoustic Frequency Accuracy: ±3%Harmonic Distortion (THD): Less than 5% (measured acoustically)Noise Signals: (3 dB bandwidths)Low Band: 125 -1,600 Hz High Band: 1,600 -4,000 Hz Broad Band: 125 -4,000 Hz Intensity Range: 35 to 120 dB HLStep Size: 5 dB, >1 dB and 2 dB Calibration Accuracy: ±3 dB Step Accuracy: ±0.5 dB ON/OFF Ratio: 70 dB minimum ENVIRONMENTAL Temperature:Storage: -40°C to +75°C Operating: +15°C to +35°C Humidity: 90% at 35°C (non-condensing)ACCESSORIES SUPPLIED Probe assembly (including contralateral insert phone)Eartips (1 pkg. each standard, special, screening)Printer paper, 2 rolls thermal, 1 roll self-adhesive Calibration test cavity, Cleaning kit, Probe mount kit (shoulder, clip, wrist band), Quick User Guide,Reference Instruction Manual, Remote (RS232 link)Dust CoverOPTIONAL ACCESSORIES Deskjet printer 1700-9613External VGA monitor 1700-9614External keyboard 1700-9615Isolation Transformer 1700-9617Service Manual 2000-0110Conversion Kit 2000-9650(V1 to V2)LANGUAGE KITS GSI TympStar Version 1English 2000-9645E French 2000-9645F German 2000-9645G Spanish 2000-9645S Italian 2000-9645I GSI TympStar Version 2English 2000-9646E French 2000-9646F German 2000-9646G Spanish 2000-9646S Italian 2000-9646I QUALITY SYSTEM Manufactured, designed, developed and marketed by VIASYS Healthcare Inc. NeuroCare Group under ISO 13485, ISO 9001 certified quality system.COMPLIANCE / REGULATORY STANDARDSDesigned, tested and manufactured to meet the following domestic (USA), Canadian, European and International Standards:UL 2601-1American Standards for Medical Electrical Equipment. IEC 601-1, EN 60601-1International Standards for Medical Electrical Equipment.CSA C22.2 # 601-1-M90Medical Device Directive (MDD) (ID No.: 0344) to comply with “EC Directive” 93/42/EECANSI S3.39, ANSI S3.6, IEC 645-1, IEC 1027, ISO 389GSI TYMPSTAR ™Middle Ear Analyzer。
蔻德罕见病中心创始人黄如方：患者绝对不会放弃自己
蔻德罕见病中心创始人黄如方：患者绝对不会放弃自己作者：郑智维来源：《民生周刊》2021年第23期“通过患者组织的力量，聚集一批有情怀的企业家、科学家，推动我国罕见病解决路径中的薄弱环节—基础科研和医学转化。
”这是40岁的黄如方为下一个十年定下的目标。
毕业于浙江大学的黄如方，是中国罕见病高峰论坛发起人、蔻德罕见病中心创始人，是我国罕见病领域的开拓者和践行者。
同时，因患有假性软骨发育不全症，他本人也是一名罕见病患者。
过去十几年间，黄如方以公益的方式将罕见病概念引入中国，让罕见病群体从鲜为人知到广为人知，并组建患者组织，推动罕见病领域制度、政策层面的改变。
此外，他还发起组织论坛，凝聚起多方力量。
在推动行业发展及问题解决时，患者组织是其中不可或缺的力量。
“其他人可能会放弃某一项研究、某一个领域、某一种疾病，但我们患者是绝对不会放弃自己的，这就是患者组织底层的内驱力。
”接受《民生周刊》采访时，黄如方说。
在罕见病领域，我国目前已有100多个患者组织。
在推动罕见病领域制度改革、患者救助等方面，患者组织发挥了巨大作用。
15年前，黄如方刚大学毕业，“那时候，全社会都不了解罕见病，不了解罕见病群体的生存状态，没有患者组织”。
毕业后的第二年，他与王奕鸥一起发起创立瓷娃娃关怀协会。
该组织致力于促进社会对成骨不全症等罕见病患者的了解和尊重，消除对他们的歧视，维护该群体在医疗、教育、就业等领域的平等权益，推动有利于成骨不全症等罕见疾病脆弱群体的社会保障相关政策出台。
“刚开始做的工作就是让大家了解、关注罕见病群体，只有了解，才能对罕见病的问题给予足够重视，才能推动问题的解决。
”回忆起当时的情形，黄如方说。
为了让更多人了解罕见病群体，他与同道一年举办的大大小小的活动有上百场，深入社区、高校、商场发放资料，利用线上线下渠道进行宣传科普，通过媒体讲述罕见病患者的故事。
期间，除了成骨不全症患者外，他接触到越来越多其他病种的罕见病患者。
转化医学(英文)
！~医药科学专业解释：转化医学；转化医学就是希望将生物医学研究的关注点放在如何将实验室的研究发现转化导向为有利病人诊断、治疗方法的提高上。
2：网络释义：a--转化或转换医学（Translational Medicine）是近两三年来国际医学健康领域出现的新概念。
b--转译医学(Translational Medicine)c--转换医学（Translational Medicine），又叫转化医学是本世纪从循证医学发展而形成的一个医学实践和干预性流行病学的理念，它融汇基础科学、社会科学、政治科学于一体...d--阿斯利康中国创新中心(ICC)初期将着重进行癌症领域临床前到临床医学之间转化医学(translational medicine)的研究。
广义上讲，转化医学(转化科学)就是使病人直接受益的对基础科学研究的应用。
Open accessAll articles published by Journal of Translational Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.Authors of articles published in Journal of Translational Medicine are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.Article-processing chargesOpen access publishing is not without costs. Journal of Translational Medicine therefore levies an article-processing charge of £1250/$2005/€1560 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.Indexing servicesFollowing publication in Journal of Translational Medicine, the full-text of each article is deposited immediately and permanently archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories in e-Depot, the National Library of the Netherlands' digital archive of electronic publications. Journal of Translational Medicine is included in PubMed and all major bibliographic databases. A complete list of indexing web services that include BioMed Central's journals can be found here.Journal of Translational Medicine is tracked by Thomson Reuters (ISI)and has an Impact Factor of 3.47.Publication and peer review processAuthors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Translational Medicine, a personalized section of the site.Portability of peer reviewIn order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from Journal of Translational Medicine, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Journal of Translational Medicine and the authors choose to submit a revised version to another BioMed Central journal, we will pass the reviews on to the other journal's editors at the authors' request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another BioMed Central journal.ReprintsHigh-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.SupplementsJournal of Translational Medicine will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.Editorial policiesAny manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.Correspondence concerning articles published in Journal of Translational Medicine is encouraged. A 'post a comment' feature is available on all articles published by Journal of Translational Medicine. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.Editorial standardsBioMed Central is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.Ethical guidelinesSubmission of a manuscript to Journal of Translational Medicine implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.Journal of Translational Medicine's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.Standards of reportingJournal of Translational Medicine supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. Checklists are available for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), observational studies (STROBE), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). For authors of systematic reviews, an additional file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.Standardised gene nomenclature should be used throughout. Human gene symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database and any enquiries, or requests for new gene symbols, should be directed via email to hgnc@. Nomenclature committees for other species are listed at /about/faq#otherspecies. For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society.Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.Journal of Translational Medicine also supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform including the ISRCTN register administered by Current Controlled Trials, part of BioMed Central Group.The trial registration number should be included as the last line of the manuscript abstract. Data and materials releaseSubmission of a manuscript to Journal of Translational Medicine implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.Nucleotide sequencesNucleotide sequences can be deposited with the DNA Data Bank of Japan(DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).Protein sequencesProtein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).Mass spectrometryCompeting interestsJournal of Translational Medicine requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.Plagiarism detectionJournal of Translational Medicine's publisher, BioMed Central, is a member of the CrossCheck plagiarism detection initiative. In cases of suspected plagiarism CrossCheck is available to the editors of Journal of Translational Medicine to detect instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative allowing screening of published and submitted content for originality.Citing articles in Journal of Translational MedicineArticles in Journal of Translational Medicine should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.Article citations follow this format:Authors: Title. J Transl Med [year], [volume number]:[article number].e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Transl Med 2009, 1:115.refers to article 115 from Volume 1 of the journal.Why publish your article in Journal of Translational Medicine?High visibilityJournal of Translational Medicine's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.Speed of publicationJournal of Translational Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Translational Medicine, BioMed Central and PubMed Central and will also be included in PubMed.FlexibilityOnline publication in Journal of Translational Medicine gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).Promotion and press coverageArticles published in Journal of Translational Medicine are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Translational Medicine's pages and on the BioMed Central homepage.In addition, articles published in Journal of Translational Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Translational Medicine. A list of articles recently press-released by journals published by BioMed Central is available here.CopyrightAuthors of articles published in Journal of Translational Medicine retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).For further information about the advantages of publishing in a journal from BioMed Central, please click here..。
GE Healthcare
Our Vision: Healthcare Re-imagined
We are striving to transform the delivery of healthcare. Our Purpose is to help predict, diagnose, treat and monitor disease earlier so people can live life to the fullest
GE Healthcare global presence
USA 21,277 / 46%
Employees
Americas 2,168 / 5% Employees L America 1,504 Canada 664
5 Yr V%
~50%
Europe & MEA
14,970 / 32% Employees
From
"Late Disease"
Symptom-based Incomplete data Managing illness Standardized treatment
To
"Early Health"
Prevention/prediction Detailed patient Info Early diagnosis Targeted therapies
Global HC Spend Profile
Screen
Inform
Localize Characterize Intervene
Feedback
Today Predict Diagnose
5%
15%
Treat 70%
Future Predict 9%
嘉康利
嘉康利培训
• 嘉康利学院：宗旨 十年树木、百年树人!嘉康利学院致力于培养心灵 环保的人才，通过嘉康利学院，我们将培养我们的伙伴成为品德正直、 诚信、团结、助人、有领导力和环保使命感的人。 – 嘉康利雏鹰训练营 嘉康利雏鹰训练营：针对刚刚从事嘉康利事业的新伙伴 嘉康利事业的新伙伴从建立正 嘉康利事业的新伙伴 确心态，培训销售技巧，到学习嘉康利公司的产品、营养知识制 定了完善的课程。让新人走进嘉康利后建立稳定价值观、培养良 好的工作习惯、从而完成从新人迈向嘉康利人的过程。参加嘉康 利雏鹰培训不仅可以学到知识，通过努力还可获得精美奖品，更 可以享受到荣誉与欢乐！ – 嘉康利学院菁英培训 嘉康利学院菁英培训：致力于打造精英团队，它将帮助嘉康利的 嘉康利的 伙伴建立具备最强战斗力与绩效的团队 最强战斗力与绩效的团队。嘉康利学院菁英培训将 伙伴 最强战斗力与绩效的团队 助您的嘉康利事业如虎添翼、虎虎生威! – 嘉康利学院讲师培训 嘉康利学院讲师培训：为培养嘉康利公司自己的讲课人才 自己的讲课人才而精心 自己的讲课人才 打造。通过嘉康利讲师培训，不仅让嘉康利的伙伴提高自身的演 讲水平，也让他们为进一步壮大自己的嘉康利事业提前做好准备。
“健康与环保”的企业文化
• • • • • • • • • • • • 2006年 嘉康利获美国环保局授命「气候领袖」 2003年 获美国营养保健期刊颁发「环境永续经营金牌奖」 2003年 获美国民间环保组织颁发「国家环保杰出奖」 2002年 获国际社会可靠组织颁发「最佳环保奖」 2002年 嘉康利获环境保护杂志颁发「年度设备环保奖」 2002年 获美国环保局颁发「气候保护大奖」 2001年 获美国直销协会颁发「明日愿景奖」 2001年 嘉康利总部获美国建筑师协会颁发「最佳节能建筑奖」 2001年 获加州环保与经济平衡委员会颁发「市长奖」 2001年 获加州环保局颁发「环境与经济领袖大奖」 2000年 世界地球日，获「环保企业领袖奖」 1990年 获「居家环保大奖」，公认为全美最提倡环保的十大企 业。
中小学教学楼建筑国外参考文献
中小学教学楼建筑国外参考文献随着社会的快速发展,校园教学楼建设越来越受到重视。
校园教学楼是学生重要的活动场所,对于学生的生活、学习方面都是非常重要的部分,充分的利用建筑的空间变化能够更加丰富学生的生活,提高学习效率,因此进一步加强对其的研究非常有必要。
就目前的情况来看,对于现代建筑其主要是强调了建筑的交流空间,给人们能够提供一个交流的空间,从而更好的愉悦师生的心情,更好的投入到学习和工作中,因此在教育建筑中进行交流空间的设计非常重要,需要引起我们的重视。
参考文献一[1]Marlyne Sahakian,Gill Seyfang. A sustainable consumption teaching review: From building competencies to transformative learning[J]. Journal of Cleaner Production,2018,:.[2]Kendra C. Taylor. Teaching decision-making and building resilience in youth –A case study to reduce the supply of vulnerable youth to sex traffickers in Atlanta, Georgia[J]. European Journal of Operational Research,2018,268(3):.[3]Li Yang,Xiaodong Liu,Feng Qian,Shubo Du. Ventilation effect on different position of classrooms in “line”type teaching building[J]. Journal of Cleaner Production,2019,209:.[4]Noriyuki Inoue,Tadashi Asada,Natsumi Maeda,Shun Nakamura. Deconstructing teacher expertise for inquiry-based teaching: Looking into consensus building pedagogy in Japanese classrooms[J]. Teaching and Teacher Education,2019,77:.[5]Jonathan L. Mezrich. Innovative Teaching Methods in Radiology—Building on the Experiences of Other Disciplines[J]. Academic Radiology,2019,26(1):.[6]Michael P O'Leary,Reed I Ayabe,Christine E Dauphine,Danielle M Hari,Junko J Ozao-Choy. Building a Single-Site Robotic Cholecystectomy Program in a Public Teaching Hospital: Is It Safe for Patients and Feasible for Residents to Participate?[J]. The American Surgeon,2018,84(2):.[7]. Transplant Medicine - Liver Transplants; New Findings from National Taiwan University Describe Advances in Liver Transpls (Efficient undergraduate learning of liver transplant: building a framework for teaching subspecialties to medical students)[J]. Biotech Week,2018,:.[8]David Malone. New Life Science Building at University of Washington designed for the next generation of research and teaching[J]. Building Design & Construction,2018,:.[9]Jacob Peng,Ira Abdullah. Building a market simulation to teach business process analysis: effects of realism on engaged learning[J]. Accounting Education,2018,27(2):.[10]Burgard,Boucher,Johnston. Building Capacity and Changing Mental Models: The Impact of a Short-Term Overseas Teaching Experience on White Teacher Candidates from a Rural Midwestern College[J]. Action in Teacher Education,2018,40(1):.[11]Baize-Ward,Royer. Questioning the Influence of a Spiritual Lens on Teaching, Empathy Building, and Meaning Making in a Community College: ADuoethnography[J]. Community College Journal of Research and Practice,2018,42(7-8):.[12]Biggs,Bowers,Bartle Angus. University and Community College Partnership: Building Teaching Capacity to Increase Underserved Student Success[J]. Journal of College Reading and Learning,2018,48(3):.[13]Johnston,George. A tool for capacity building: teacher professional learning about teaching writing[J]. Teacher Development,2018,22(5):.[14]刘嫦娥,潘瑛,常学秀,孟祥怀,秦媛儒,段昌群. 基于教学–科研有机融合的环境类复合型人才培养模式探讨—以云南大学环境科学专业建设为例[J]. 教育进展,2018,08(02):.[15]孟凡云. 传统教学与慕课教学方式结合的课堂教学模式构建研究—以民族学专业《中国民族志》课程为例[J]. 社会科学前沿,2018,07(09):.[16]Melinda Hermanns,Danice B. Greer. Building God?s Kingdom Through Strengths-Based Teaching[J]. Journal of Christian Nursing,2018,35(4):.[17]O'leary Michael P,Ayabe Reed I,Dauphine Christine E,Hari Danielle M,Ozao-Choy Junko J. Building a Single-Site Robotic Cholecystectomy Program in a Public Teaching Hospital: Is It Safe for Patients and Feasible for Residents to Participate?[J]. The American surgeon,2018,84(2):.[18]Frew Emma,Platt Maia,Brown Heather,Goodman Allen,Seidler Elizabeth,Spetz Joanne,McIntyre Di. Building an international health economics teaching network.[J]. Health economics,2018,27(6):.[19]Carla Viviana Coleman Cordova,Nilanjan Banerjee. INTERDISCIPLINARYTEACHING STRATEGIES for Designing and Building Effective Smartphone Applications[J]. GetMobile: Mobile Computing and Communications,2018,22(1):.[20]McGreevy James M,O'Shea Jennie M. Building a Simulator with Life-like Realism for Teaching Abdominal Operations.[J]. Journal of surgical education,2018,:.。
CarePlus 快速参考指南说明书
Magellan Healthcare and CarePlusQuick Reference GuideEffective Date: Jan. 1, 2018__________________________________________________________________________________Plan InformationMedicare AdvantageContact InformationProvider Authorizationand Eligibility Line1-800-424-1760 Counties in Florida include Brevard, Broward, Clay, Duval, Flagler, Hernando, Hillsborough, Indian River, Lake, Marion, Miami-Dade, Orange, Osceola, Palm Beach, Pasco, Pinellas, Polk, St. Johns, Seminole, Sumter, Volusia Call this number for member care inquiries, outpatient preauthorization when required, higher levels of care preauthorization, and member eligibility verification.National Provider Services Line TTY/TDD 1-800-788-40051-800-424-1760 for 711relay serviceCall this number for general inquires, includingcredentialing and network status, or for any othernetwork administrative issues.Claims 1-800-424-1760 Call this number for claims information. You also maycheck the status of your claims after secure sign-in on theMagellan provider website.First-Level ReviewPrimary Fax Backup Fax Magellan AppealsPO Box 1718Maryland Heights, MO 630431-888-656-57121-888-656-5061Submit a first-level claim dispute in writing to MagellanAppeals.Second-Level Review Website CarePlus Health Plans, Inc.11430 NW 20th Street, Suite 300Miami, FL 33172Provider Operations departmentSubmit a second-level review in writing to CarePlus.Access our website for further information about servingMagellan members, including:•Magellan Provider Handbook•Medical Necessity Criteria•Clinical Guidelines•Claims Submission and Status•Provider Data Change Form•Provider Profile•Provider Focus Newsletter•And much more.AuthorizationsMagellan uses our streamlined clinical management model for outpatient treatment for CarePlus members. In this model, for most cases, providers do not need to preauthorize routine outpatient services or submit treatment request forms for continued care. For additional information regarding our outpatient model and for requesting higher levels of care, go to, select Providing Care, then Initiating Care, then Authorization.Claims SubmissionSubmit claims online by signing in with your secure username and password at . Be sure to identify the P.O. Box below for claims submissions for this plan. If you do not have Internet access, use the standard CMS-1500 claim form or the UB-04 claim form. Claims must be filed using the HIPAA-compliant CPT code(s).Submit paper claims to:Magellan HealthcareP.O. Box 2215Maryland Heights, MO 63043。
深圳市伯明翰生物科技有限公司_企业报告(供应商版)
100.0
公告时间
是否中 标
2022-08-18 未中标
四、服务客户
4.1 关联客户中标情况
深圳市伯明翰生物科技有限公司主要关联客户有深圳市福田区建筑工务署。近 1 年关联次数分别达到 1 次。
本报告于 2023 年 08 月 18 日 生成
5 / 10
*关联采购单位是指，供应商参与投标入围的采购单位。
序号
项目名称
招标单位
中标金额 （万元）
公告时间
是否 中标
广东省智能科
1 广东省智能科学与技术研究院天能电泳 学 与 技 术 研 究 10.5
及转膜系统采购项目
院
2023-06-20
未中 标
2 华 南 理 工 大 学 生 物 智 能 体 成 型 系 统 华南理工大学 （CLF0122GZ18ZC63）中标结果公告
4.2 主要客户投标项目
（1）深圳市福田区建筑工务署（1）
序号
项目名称
招标单位
中标金额 （万元）
公告时间
是否 中标
1
中山大学附属第八医院（深圳福田）生物 实验室（细胞房）电动移液器、移液枪
（器）（1 套 4 支）采购项目中标公告
*按近 1 年中标金额排序，最多展示前 10 记录。
深圳市福田区 建筑工务署
1.2 业绩趋势
近 3 月(2023-06~2023-08)：
近 1 年(2022-09~2023-08)：
本报告于 2023 年 08 月 18 日 生成
1 / 10
近 3 年(2020-09~2023-08)：
1.3 项目规模
1.3.1 规模结构 近 1 年深圳市伯明翰生物科技有限公司暂无中标项目 近 1 年(2022-08~2023-08)：
WHO精液检查第五版
2
HCV hepatitis C virus 丙肝病毒 HIV human immunodefciency virus 人免疫缺陷病毒 HOP hamster oocyte penetration 仓鼠卵穿透 HOS hypo-osmotic swelling 低渗肿胀试验 HPF high power field 高倍视野 HRP horseradish peroxidase 辣根过氧化物酶 HSA human serum albuminxiv 人血清白蛋白 IV HTF human tubal fuid 人输卵管液 IB immunobead 免疫珠 IBT immunobead test 免疫珠试验 ICSI intracytoplasmic sperm injection 胞浆内精子注射 Ig immunoglobulin 免疫球蛋白 IM immotility 不动 IQC internal quality control 内质量控制 IU international unit 国际单位 IUI intrauterine insemination 宫腔内人工授精 IVF in vitro fertilization 体外受精 KRM Krebs-Ringer Medium Krebs-Ringer 培养液 LIN linearity 线性 LLQ lower limit of quantifcation 定量下限 LPF low power field 低倍视野 MAD mean angular displacement 平均角位移 MAI multiple anomalies index 复合异常指数 MAR mixed antiglobulin reaction 混合抗球蛋白反应 NA numerical aperture 数值孔径 NP non-progressive (motility) 非前向的（活力） PBS phosphate-buffered saline 磷酸缓冲盐溶液 PDCA plan, do, check, act PMA phorbol 12-myristate 13-acetate (12-)十四酸佛波酯(-13-)乙酸盐 PMSG pregnant mare serum gonadotrophin 孕马血清 PNPG p-nitrophenol glucopyranoside 对硝基苯酚吡喃葡萄糖苷 PR progressive (motility) 前向的（活力） PSA Pisum sativum agglutinin 碗豆凝集素 QA quality assurance 质量保险 QC quality control 质量控制 RCF relative centrifugal force 相对离心力 RI refractive index 屈光指数 RNA ribonucleic acid 核糖核酸 ROS reactive oxygen species 活性氧类物质 rpm revolutions per minute 每分钟转速 SD standard deviation 标准差 SDI sperm deformity index 精子畸形指数 SDS sodium dodecyl sulfate 十二烷基硫酸钠 SE standard error 标准误
印度展会客户资料
HOSPIMedica India, New Delhi 展買主資訊大曝光!親愛的顧客：2007年環訊國際總計參加全球近70個展會，我們堅實的參展陣容將為您代勞，讓無暇與會的您也能取得最即時的國外展會訊息。
在展會期間所收集的買主訊息我們會在展會結束後整理建檔並以最快的速度傳送給您。
如欲取得更多買主名單，請利用celia_tseng@ 與我們聯絡。
謝謝。
展會名稱:HOSPIMedica India,New Delhi 展會期間:2007/3/9-3/11CONTACT TITLE COMPANY COUNTRY TEL FAX E-MAIL WEB SITE BUSINESS PRODUCT 91-1123285196sjdil@ SUNEET MAHAJAN DIRECTOR ORION MARKETER'S INDIA 91-0183222024491-9814298260orionmarketers@sancharnet.in D R1/HOME1/O2,10S.S. RAJ KUMAR CINDRELLA MARKETING INDIA 91-9842136073cjndrellamad@ W HOME7,8,11,12,13/H5,7,9,10/E1,6,7/D3,7,9SHAILESH KATIKAR MARKETING STAT DIAGNOSTIC SERVICES INDIA 91-222511242491-2225157265info@ I/D H7/D9/O11MANOJ KUMAR SHAH MANAGING M ASTEL IMAGING & RESEARCH CENTRE (P) LTD INDIA 91-542222320191-2223604manojshah@ I/D H8/O2VIPIN SHARMA BIOMEDICA MAX HEART MAR HEART & VASCULAR INDIA 91-112651505091-1126510050mnipiv123@yahoo.co.in O R6/HOME14/H4,7,9/E1,2,3,4,7,8/O1,2,3MAJ. SANJEEV BHATIA MEDIAIDS INDIA 91-172254351091-2543510mediaids_2000@ I/W HOME2,11/H3,7/D6,9ANMOL KOONER DIRECTOR O DIGITAL MEDICAL SYSTEMS INC.INDIA 91-172226060391-1722274322sales@ I R2,4/HOME1,2,3,5,6,8,12,13/H1,2,3,5,6,7,8/E4,5,6/D7DR. AMAR JEET SINGH PAIN CLINIC INDIA 91-2689257891-9818879779sehdevamarjeet@yahoo.co.in I R1,6/HOME3,11/E4,8/O10VIRENDRA NEGI PHYSIQUE EQUIPMENT CO.INDIA 91-0571248235391-0571*******physiquipment05@yahoo.co.inD R1,HOME2,3,4,5,6,9,10,11,12,13/H1,2,3,4,5,6,7,8,9,10/E1,2,3,4,5,6,7,8/D4,5,8/O1,2,3,5,9,10MAULIK R. SHAHJ. R. ENTERPRISE INDIA 91-79309200607930920060@ I/D R6/HOME2/H6/E2,3/D4D.C HAKRABORIYFRONTIER SAFETY PRODUCTS PVT. LTD.INDIA 91-9311341800dilipchak@ I R6/H2CHANDRASEKHARADIRECTOR FOUR-C-TRON INDIA 91-802525250691-8025258392fourctron@ M/D R5/H2,5,9/E7/D7,9/O2,11MANISH SABHARWALPROPRIETOR DR.SABHARWALS WOUND CARE 91-179565626091-1722565789drsmpl@ E/MHOME5/H5,7CLEMENS MOHRMEDICAL TECHNOLOGY PROMEDT CONSULTING GERMANY 49-0689458102049-06894581021info@ O R6SYED NASEERMEDICO SCIENTIFIC SERVICE CENTRE INDIA 91-01942313816medicoservice@sancharnet.in D R1,3/HOME2,5,7,8,9,10,11,12,13/H3,4,5,7,8,9,10/E1,2,3,4,6,8,/D3,4,5,8/O2,5,7,8ARVIND JOSHIJOSHI ENTERPRISES 7714032893joshienterprises_raipur@ I R1/HOME13/H2/E4,7/D1/O1,2,3,11S.B. NAINMEDITECH ELECTRONICS INDIA 91-1127565949sbnain@ I/M R6/HOME5/H1,2,3,4,5,6,7,8,9,10/E1,2,3,4,5,6,7,8/D5/O1,2,3,4,5,9IFTIKHAR AHMADMALABAR TRADERS INDIA 91-01942459734malabarsgr@yahoo.co.in D R1,3/HOME2,5,7,12/H1,2,4,5,6,7,9/E1,2,3,6/D1,3,4,9/O1,5,8,9,11VINOD TRAKROOCHIEF EXEC VALLEY MEDICAL SYSTEMS INDIA 91-222293713991-2227897194vms91in@yahoo.co.in I/D HOME5/H10/E1,8/O2,11K. T. MURUGANLABCARE INSTRUMENTS INDIA 91-112756595891-1127345935labcare@ D/R R6/HOME5,7/H9/E8/O11S. K. KAUSHALMEDITECH INTERNATIONAL INDIA 91-2172270494991-01722721000meditech@sancharnet.in D GIRISH GUPTAGUPTWA MEDI-EQUIP. CO.INDIA 91-01615069546giri100100@yahoo.co.in D HOME2/H4,6/E7/D8AJAY NAGPALPULSE-WAVE STETHOSCOPE INDIA 91-23852882response@ www.pulsestethoscope.co I/E/M R6/HOME7,12/E6KETAN PATELBINNY'S HEALTHCARE LTD INDIA 91-7964503004binnyshealthcare@ www.skyline.trade-india.I/E/M R6/HOME5/H5,9/E2,7,8/D1,2,3,4,5,6,7,9DR. JITENDRA R. VEERSAMARTH SURGICAL AND HEALTHCARE COMPANY INDIA 91-2312644574jitendraveer@sancharnet.in I E1,7/O2,5,11VINOD KUMARA & A INC INDIA 91-113299449591-1125597002info@ I/D HOME3,5,9,10/H9,10/E3,4/D3,9/O2未发推荐监护和超声多普勒MICHELE CICIGOIBREAMER LIMITED HONG KON 852-27219887852-27219809m.cicigoi@ D HOME3,7,8,9,10,12JAYANTICENZER INDUSTRIES LIMITED INDIA 91-222389542791-2223800706cenzer@ I HOME7,9,10,12/E4VIKASH SINGH PARIHARMONITORS,U MEDITECH INNOVATIONS INDIA 91-114247020591-1142470521mtechindia@ www.meditechinnovation I R1,6/H3,4,5,11/E1,3,4SANDEEP SINHAHOSPILINE EQUIPMENTS PVT. LTD INDIA 91-01122460362hospiline@hospiline.in M R5/HOME5/H10/D4/O5ASHISH BHANDARIHEAD-SALES MULTIVAC INDIA PVT. LTD.INDIA 91-124229180191-1242291803ashish@ I/E/M R1,3,5RABINORA N. SENAPATIR. S. ENTERPRISERS INDIA 91-253004491-06742536921rabindra_surgical@dataone.in D R1,2,3/HOME1,2,5,13/H4,8/E2/O3G. CHANDRASEKHARMANAGING MEDICAL PRODUCTS INDIA 91-402789250091-4027892600medisun@.in W/D HOME1,5,8/H5,10/E1,2,6/D6/O1,2,3RAJEAH DORHIB.E.(C). D.B.I SMILE MARKETINGS INDIA 91-02656622891smilemarketings@ D/R R1,3,4/HOME1,2,5,7,8,10,11,12,13/E2,7,8/D1,3,6,7,9/O8,9,10RAJESH DAGAMANAGING PLASTI SURGE INDUSTRIES PVT. LTD.INDIA 91-72167413091-721670403psidispo@ I/M HOME5,10,12/D4,9/O9ASHOK KUMARMANAGING JAI HEALTHCARE PVT. LTD.INDIA 91-0112731335391-01127312611jaigroup@ I/D SWENTSWASTIK ENTERPRISE INDIA 91-288257029591-2882552845swent_ad1@sancharnet.in E/M R6/H11/D3HARJEET SINGH ARORACADILLAC MEDICAL AGENCY INDIA 91-9910262769I HOME3/H5/E2/D3/O2HOSMAC INDIA 91-222686344791-2226863465hosmac@ D R6/HOME5/H1,2,3,4,5,6,7,8,9,10HANIRH MALHATRAC.E.O.MONARCH SURGICAL INDUSTRIES INDIA 91-112638523791-1126389237monarch1@ www.monarchsurgical.co I/M/D H6,7N S K. KRISHNANMANAGER M EDICARE EQUIPMENTS PVT. LTD.INDIA 91-222540549091-25452233sales@ I/M/W H6,7/E2S. K. VADHVANIMAYUR ENTERPRISES INDIA 91-11269534891-1126942222skvmedicons@ I/M R1,3/HOME3/H1,5,8ABHINEET TALWARMANAGER U NITED SURGICAL INDUSTRIES INDIA 91-2214960091-01122152679unisurg@.in I/M H/E VIPIN AGRAWALB. TECH DEEPAK ENTERPRISES INDIA 91-112681019591-26810199vipin@ www.deepakenterprises.c I/M H1,5,6,8,10AMOLAK SINGHINTERNATIONAL ELECTRO MEDICAL CO.INDIA 91-112327868691-1123268687iemco@ I/E R/HOME2,9,11/H1,6/E1,2,3,4,6,8/O3,8,10V.K. SHARMAS.R. ENTERPRISES INDIA 91-25817479sr.enterprises@ I R1/HOME5/H4,9,10/E1,4,8/D4,9/O3,4,9,11CHINTAN KOTHARISURGI PHARMA INDIA 91-22637548391-2222036758surgipharma@ I R6/H6,12/D1,3,9/O9JIMMY TRAN FRANCE 33-0556********-0556217903jimmy.tran@ E ANURAG SETHCONTINENTAL SURGICAL EMPORIUM INDIA 91-232455591-01123246666continentalsurgical@ www.surgicalshoppe.co.i E/M R1,3,4/HOME1,5/H1,2,8DR. KHACID RAZA AZMICHAIRMAN HI-TECH MEDICARE DEVKES PVT. LTD.INDIA 91-551220997791-5512201396hmdpl@ M R/D DEEPAK JAINCEO AMAZING HEALTHCARE DEVICES INC.INDIA 91-112572176691-1142430966deepak_jain007@ www.amazing-healthcare I R1,3,5/HOME2,3,5,8未发，推荐小的，指甲，掌式DR. T. S. KUKREJAEXECUTIVE AMRI HOSPITALS INDIA 91-332335955991-3323353327tskukreja@amrisaltlake.in www.amrihospitals.in O R1,3,4/HOME1,2,3,5,6,7,8,11,12,13/H1,2,4,5,6,7,8,9,10/E1,2,3,4,6,7,8/D1,2,3,6,7,8,9/O1,3,6,7,9,10SYED ABDUL SALAMNOBSA HEALTHCARE INDIA 91-442848367391-4443518519nobsahealthcare@ I/D R/HOME/H4,5/E1SURESH GHIMIREMANAGING NURAZ PTE. LTD.NEPAL 977-437410977-1437404nuraz@.np I/D R1,2,3/HOME2,13/H3,4,8,9/E1,2,3,4/D3/O1,3,4,10SANTOSH NAVALEELECTRONIC OMAX TECHNOLOYIES INDIA 91-0217231381691-2313816spr_omaxtech@sanchamet.in I/M/D R2/HOME1,2,5/H1,4,6,10/E1,2,3,6,8S. RAVIMARKETING THE ADVANCED MEDICAL SYSTEMS INC INDIA 91-442617422491-4426175012amsinc@.in I/E R2,5/HOME2/H4,6,7,9/E1,2,3,8/D2,3,4,5,6,8,9/O1,2,3,5,6,7,8,9,10,11P.CHANDRAMOULI MAIYASERVICE MA MOOLAA TECHNOLOGIES PRIVATE LIMITED INDIA 91-0112668709591-01126687008mtpl.del@ D H4/E3HEM RAJ KALRASALES EXEC BECKCEM DRUG INTERNATIONAL PVT. LTD.INDIA 91-115171610391-1129842624beckcem@.in I R1,3/HOME5TIBERIU POPCOUNTRY SA S.C. REDOX CLUJ S.R.L.ROMANIA 40-26441642740-264416427redox@cluj.astral.ro www.redox.ro I/W/D R6/HOME7,13/H2,5,10/D1,3,6,7,9/O3N.V. RAOJ. V. INDUSTRIES INDIA 91-08415237400contact@ M H1ER. BHARAT SINGALASK TECHNOLOGIES INDIA 91-184222023691-1842220235rpexport@ D H9/E2,4/O2PRAVITA LYERDIRECTOR A CHARY PUBICATIOUS PVT. LTD.INDIA 91-2555642891-022********charypublications@ M H9AMIT KEJRIWALCOSMIC TRENDS PVT. LTD.INDIA 91-113200136091-1127353153amit@ I R3/HOME5,7,11,12/E2/D1KETAN H. KAPADIAA-1 PHARMA INDIA 91-222822307091-2228376741a1pharma@ I/D HOME6,7,10,12/E2/O2,9,10,11NARESH B. MANDOTBLUMEI SURGICALS & PHARMACEUTICALS PVT. LTD.INDIA 91-2650554591-2226509407mandot@.in M HOME5/H2/D2,3MANAJ CHAPRARELIANCE MEDISYSTEMS INDIA 91-129406707791-9810294548reliancemed@ I HOME1,2,5,7,8,10,12,13/E1,2,3,4,5,6,7,8/D1,3,5,9/O1,3,9ANKIT MALHOTRAHEALTH POINT INDIA 91-0112090861791-01141621991healthpoint.delhi@ I/M R1,3,6/HOME5ROHIT MADANKIND REMEDIES (P) LTD.INDIA 91-172504999391-1722613702info@ I D RIAZ HUSSAINADVANCE MEDICAL SYSTEM PAKISTAN 92-224065592-021*******riaz69@.pk I R1/HOME2,8,12/H2,5,6/E1,2,3,4/D8/O2,5R.K. ANANDPRODUCT M R ECORDERS & MEDICARE SYSTEMS (P) LTD. INDIA 91-172265870191-1722653415anand@ I HOME5/H4,9/E1,6,7,8PRABHAKAR JOSHICEO BILINK INTERNATIONAL INC INDIA 91-291329087691-2912626471info@ I/E/M H2/D3ELLENDRA THOUDAMDELBROS INDIA 91-0385241109191-03852413772delbros@sancharnet.in D R1,3/HOME1,2,7,8,12/H1,4,5,6,7,9/E1,2,3,4/D1,2,3,5,8,9/O2,5,8PRAVEEN RAOMANAGER A SHISH HEALTHCARE INDIA 91-222636655591-2226399288info@ www.ashishhealthcare.co I R6/HOME5,7/H7,9/E2RAJIV K SHARMAGENERAL M J UBILEE MEDICARE LIMITED INDIA 91-114173018191-1141730182rk@ I/D E1,2,6R.P. PALPAL SURGICAL INDUSTRIES INDIA 91-6632209391-01123864591palsurgical77@ E/M/W/D R 1,3,5DR. JIJU JOHMPRESIDENT JJ HEALTHCARE PVT. LTD.INDIA 91-480270048991-4802705593jjdental@ I H/E1DAVINDER PALITRIVENI MEDICAL SYSTEMS INDIA 91-01165244827meditrans2002@ I/D YATISH SHARMADIRECTOR M MEDICROSS PATIENT C 91-116515825391-1123819275medicross_2000@ I/D R4/HOME3,5,7,8/H5/E2/D3/O8,11MOHAN SINGH DIRECTOR HIND HYDRAULICS & ENGINEERS INDIA 91-402900591-1292234294hind@ I R1,2,3,4,5/HOME1,2,3,4,6,7,8,9,10/13以下是我們為您精選的164家買主名單，希望環訊‧貿易風提供給您的第一手資訊能為您的企業帶來跨國的新商機！SCOTT DAMRON SUPPLY CHAIN IMPORTS USA1-77081958581-7702001519sdamron@ w ww.supplychainimports I R3,4/HOME1,3,8/E4BHUSHAN KANDHARI GLOBAL CHIPS INDIA91-01155193974globalchips2004@yahoo.co.in R/O R6/HOME6,8/H1/E9/D10/O1KIRAN K. SHRESTHA TECHNICAT SEROLAB NEPAL977-155********-14228816serolab@.np .np I/D HOME1,3,5,9,10,13/H3,5,7,9/E2,6/D6/O11VINOD KATYARA SHAKTI SURGICAL & FITNESS INDIA91-0792*******shakti_sj@yahoo.co.in I/E/W/CR1,3/HOME1,2,3,6,10/H1,10/E2,7/D6,9ANIL SHETE B.E.NIKHIL MEDICO EQUIPMENTS INDIA91-2532355703nmedico_nsk@sancharnet.in MGULSHER AHMAD GULZAR KEEPING PACE WITH TECHNOLOGY INDIA91-931273714591-11269443info@ www.gulzar.in I/E/M/D D8/O5RAKESH MOHAN CHIEF EXEC SUKALP MEDTECH INDIA91-171266208591-1712619232sukalpmedtech@ I H5,7/E1,3/D6/O1,2,3,5HYUN SU, LIM MARKETING KOEL & T.I.D CO LTD KOREA82-32814085682-328140852iloveindia@ E/M H2,5,7/E3SHYAMA CHARAN TIWARI CENTRAL INDIA INDIA91-731270688891-7312702121cisaindore@ I R1,2,3,4,5,6/HOME5,6,7,8,11,12,13,14/H3,4,5,6,7,8,9/E1,2,3,6,7,8/D1,3,4,5,6,8,9,10/O1,2,3,4,9MANISH MALIK EXECUTIVE ARTEMIS MEDICARE SERVICES PVT LTD INDIA91-124238300291-1242383351manish@ www.artemishealthscienc O HOME1,5,10,12/H1,4,5,6,7R. SOMASUNDARAM MANAGING SRI MED SYSTEMS INDIA91-443091373091-9841035773rangind@ D R6/HOME5/H4,8,9,10/E6DR.GYAN SHAIKH ENNAR EXPORTS INDIA91-226591712891-2228702359ennarexports@ E/R HN. MANSUR KHAN CHIEF EXEC BIOSENA LIFE SCIENCES INDIA91-0802343866691-08023438659nmk@ M R2,5/HOME2,10,12/H4,8/E7/D3NIKHIL BATRA MANAGING LIFECARE MEDICAL DEVICES INDIA91-2384688891-23846888lifecaremedicaldevices@yahoo.co.in I/D/R R3,5/HOME2,3,7,8,9/H1,4,6/E2,7/D9SANJAY SHIRWALE INDITECH MEDICAL SYSTEMS INDIA91-2026817172M E1,3,6,8/O10URIEL ROSEN GENERAL M U RIEL ISRAEL972-48214149972-48214107info@uriel.co.il www.uriel.co.il I HOME3,5,11,13LALIT MANOCHA MANOCHA SURGICALS INDIA91-2713415491-01142283450manochasurgicals@yahoo.co.in W D3SATISH NARULA ATLAS SURGICAL COMPANY INDIA91-116547990791-1127141952shyamnarula2000@yahoo.co.in M H2,4,5,6M. BALAMURALI SENTHIL CEO BEST MEDICAL INDIA91-452435295291-4524352952ceo@bestmedical.in www.bestmedical.in I/D R1,2,3,4/HOME2,5J. B. DUTTA MANAGER T OKHEIM KAIZEN PRIVATE LTD INDIA91-01142576402jagbandhu.dutta@ I/M/W HOME5PARAG THAKKAR RANISH IMPEX PVT LTD INDIA91-226637781591-2223450133ripldiamondbp@ I R1/HOME6,7/E2/D3,6VIJAY CHADHA RAJDHANI SURGICALS INDIA91-2386067591-27473755I R1/H1,2,5,6/E2,3/D5AIZFI MEDICAL EQUIPMENTS INDIA91-981157463391-01155434259W H3/E3,6MOFID KADIR AHMAD SR. SALE & SMAYANK MITTAL SUMANGAL PHARMACY INDIA91-120285733391-1202702526sumangalpharmacy@ E R1,3/D1,9/O4K,8JAN-ERIC BIALEK PROKURIST A NDREAS FAHL MEDIZINTECHNIK-VERTRIEB GMBH GERMANY49-022*********-022*********www.fahl.de I/M ESANJEEV POYEKAR INTERMED SERVICES INDIA91-022********ims_sanjeev1@yahoo.co.in D R1/HOME5/H7/O2ARJUN BOROLE MANAGING ELECTROART INDIA91-202749339491-2027493394electroart@ M R6/E6/O2V.K. KOUL DIRECTORCELLMED TECHNOLOGIES INC.INDIA91-112731016991-1127310169cellmed@ www.cellmedtechnologie I/D R1,3/HOME1,5/H1,4,7,8/E2HYTEC EQUIP INCR INDIA91-9444572098hytecequipincr@yahoo.co.in D HOME5,13/H7,10/D6,9/O827-032941519127-0329445005dion@mplanet.co.za I R3/HOME3,5/H6/E2,4/D1,3,5,6,7,9/O9DION NAIDOO SHESA MEDICAL SUPPLIERS SOUTH AFRJANKAY NIGAM SR. AREA SA PHARMACEUTICALS LIMITED INDIA91-2582590105 91-25825606eldernd@ D/O HOME5/H4/E2SUNIL TANEJA SYSTEM ELEKTRONICS INDIA91-112981449291-1151721506systemelektronics@ I D1/O2,3,4PV REDDY MANAGER G REENSTAR INTERNATIONAL INDIA91-402780025891-4027808599pvreddy@ I/E R1,2,3,4,5/HOME1,2,3,4,5,7,8,9,10,11,12,13,14/H1,2,3,4,5,6,7,8,9,10,11/E1,2,3,4,5,6,7,8/D1,2,3,4,5,6,7,8,9,10/O1,2,3,4,5,6,7,8,9,10,11,12RAJA RAUF BUSINESS A P ROLIFECARE SYSTEMS PVT. LTD.INDIA91-2634846391-26348461prolifecaresystems@ www.prolifecaresystems.I R6/HOME2,14/E2PROF. G. NARASIMHALU DAYANANDA SAGAR INSTITUTIONS INDIA91-0802100797091-8026660789gnbiomedical@ I/D HOME5/E1,2,3,6,7Y B. SAMANT CHAIRMAN NASAN GROUP INDIA91-0202543129091-2025463540nasan@ M E1,6,712月8日发送B. S. BIRADAR PROP.SAI MEDI BED CO.INDIA91-5567898091-9810709694M H1/E8BASANTA KUMAR AREA SALES NOBLE FIRE FIGHTING INDUSTRIES INDIA91-222818913291-2228189134nffi@bom5,.in E/M R6/HOME5/H8/E9/D10/O12DR. RAJIV SHARMA C.E.O.KRUISE DIAGNOSTICS SERVICES INDIA91-922833694191-9228336942kruise_diagnostics@ I/M HOME5/H3,7,9SUKHWANT SINGH AVAL MEDICAL SYSTEMS INDIA91-5549189991-01125708963mes@.in D H4,8,9,10/E1,7,8O HOME6/H/E/DDR. BHARAT GADHAVI MEDICAL DI STERLING HOSPITAL INDIA91-794001190291-7940011166drbharatgadhavi@sterling.co.in BR BIOMEDICALS PVT. LTD.INDIA91-112689727491-9818345414brbiomed@ D R/HOME5/H7/E4,6/O10MANOJ JHA SR.SALES EXJAGTARAN SINGH MANAGEME JAGSONPAL PHARMACEUTICALS LIMITED INDIA91-11264945192491-9810019554materials@ M HOME7,10,13/H10/O1SUDHIR JOSHI DIRECTOR NEXUS INFOTECH LTD INDIA91-112623055591-1126416683businessbrains@ I/W/D R6/HOME2,3,9,10,11/O3,4,6,9VIJAY CHADHA ORIN INDIA INDIA91-01165643496oriinindia@ E/M H1,6,7,9/O5,7,9JAYSANKAR MANAGING JAYON INDIA91-491252608791-4912526088nambiardevan@yahoo.co.in M H2/D1,2,3,6RASA CHAKRAVARTY MARE MEDICAL SYSTEMS LTD INDIA91-332418530691-3324123446raja@ I/D R6/H10/E7,8/D9HARBHAJAN SINGH BIOBUSINESS DEVELOPMENT AGENCY INDIA91-115596550791-1125596820biobusiness@.in I/W H3,5,7/D3,6,9/O11SANJIV SOLANKY FORTIS HEALTH WORLD INDIA9910621100sanjiv.solanky@jorbshealth C/O R1,2,9,10/H4,8/E4,7RANGANA THA SRI LAKSHML SAEXNNC CO INDIA91-0413224479091-0413*******laxmiscientific@yahoo.co.in D R1,3/H5,6,7/E7/O2VISAY SETH SETH PHARMA INDIA9336944460sethpharma@recliffmail.co.in E/M R6/HOME14/H5,10/D9MR. JITENDRA S. GOYAL MLS SWISS MEDICAL STOR INDIA91-3210223D R/HOME/H/D/OA. K. SINGH MANAGER S IOMOND PHARMACEUITICALS PVT. LTD INDIA91-9350287291-01125711549richne416@yahoo.co.in I/E/M R1,5/HOME3,7,13/H1,7,9/E1,8/D1,2,4/O5DHEERAJ NAGPAL VNITED SCIENTIFIC INDIA91-2386709391-22410155dheeraj_star@ I/E/M/D R1,6/HOME2,3,5,7,8,9,10,11,12/H1,2,4,5,6,7,9/E3,4,8/D6,7,8,9/O1,3,5,8MANOJ SHARMA RESIDENT D THEA-TEX HEALTHCARE PVT. LTD INDIA91-0250309539391-025********contact@ I/M D4,9R/HOME/HDR. SATISH S. GEHLOT M. B. B .S.YASH HOSPITAL INDIA91-029********yashhospitalrescue@ O/HOSPITT.R. CHHABRA SAI MEDITECH SERVICES INDIA91-0130224888991-9416264303R R6/HOME5/H4,5,6,9/E1,3,4,8/D5,8/O11MD. KAMAL HOSSEIN CEO DIGITAL MEDICAL SERVICES INDIA91-008802814185491-0088028141854digitalkh371@ I/W/D HOME2,5,9,10/H1,2,3,4,5,6,7/E/D/O1ANIL CHOUDHARY GENERAL MEDICAL EQUIPMENTS INDIA91-0120432367691-01204323675gmemedical@ M H11/O2,3DEVENDRA PANCHAL ALFRONE CORPORRTION INDIA91-0794*******info@ I R6/D1,6,9SABU JOSEPH FORTUNE TECHNOLOGIES INDIA91-04843090821fortecindia@ D R6/HOME5/H5/E9/D6,10/O9,12AUINASH KARNANI AK PRODUCT INDIA91-0332287325091-03322803623akproduct2004@yahoo.co.in I R6/HOME14/D6,10RAHUL ENTERPRISES INDIA91-024********I/D/R H2,4,7,9/E1,2SURENDRA SHRIVASTAVA R. P. ENTERPRISES INDIA91-942530105191-4260105surendrashri@ W/D R3,6/HOME5,7,8,9,12,13/H3,5,6,7,9/E2/D3,4,9/O11R1/H1,2,3,4,5,6,7,8,9,10SANDEEP KUMAR ADMINISTRAMETRO HEART INSTITUTE INDIA91-0129228919091-01292263589O/HOSPITELITE ELECTRO MEDICAL EQUIPMENT (P) LTD INDIA91-0425659266191-0452*******elite_mdu@ D E4,8ELITE LNDIA DIABETIC FOYASIN SALYA OPERATIONSSALYA GROUP UK44-177255568644-1772555687yasin@ I/W/D R/HOME/H/E/DLIFELINE HEALTHCARE LIMITED INDIA91-8802955166691-88029560143I R/HOME/H/E/D/OK. G. SALEHUDDIN HIRU MANAGRINGAMANULLAH BADAL CHIEF EXEC ACCESS MEDICAL SERVICES INDIA91-933579091-88028316393info@ I R/HOME/H/E/D/OJOY ALAPPAT DIRECTOR BION SCIENTIFIC INDIA91-04843024734bion05@ I E1,2,3,4,5,6,7,8,9AJAY BHARDWAJ DIRECTOR AB MARKETING INDIA91-0612329898291-2229081bhardwajajay1@ I/D H7/E1,3,7/O5SANDEEP ZAWAR KALAGAR INDIA91-0202422283291-020********zawarg@ I/M/D R1,3/HOME1,5/H1/E1,3,4/D9/O1,3,7,9BHAYH. R. SHOH AIMS MARKETING INDIA91-80-2662233391-8051204454aimsmarketing@ I/W R6/HOME2,5,11,13/H1,2,3/O10D.S. RATHORE TECHNOMED INDIA91-0141264043591-01412641284technomed@ D H4,10/E4/D2/O11ALPESH SHAH SHAH BROTHERS INDIA91-952502509609I HOME1,2/H1,6S.K. PUROHIT SHAILTECH SYSTEM INDIA91-0755273622591-0755*******shailtech@ /shai I/D R1/HOME2,3,5,7,8/H6/E2/D5,812月8日发送 有回复RASHID A. BUTT CEO INTERNATIONAL TRADING CORP INDIA91-2480087itcorp1@ D R1,3/HOME3,5,6,7,8,9,10,12,13/E1,6/D1,3,9/O10BENNEY M. REMEDIES UNLIMITED INDIA91-0796*******remedies@ M D1,2,3,4,5,6,7,8,9,10AKHILESH SINGLA P.P.H. SALES CORP INDIA91-01802661737akhilpph@ M/D H6/D8/O2DR. SHEIKH MOHIUDDIN JESS CHEMICAL& PHARMACEUTICAL WORKS(PVT) LTD INDIA91-8802935339191-029317306addin2@ O/HOSPITR/HOME/H/E/D/ONARENDRA JINDAL ELIXIR LIFESCIENCES PVT LTD INDIA91-0135271347191-01352651120elxelljjms@yahoo.co.in I/M/D R1,4/HOME2,3,5,6,7,8,12,13/H1,2,3,4,5,6,7/E2,3,7/D1,2,3,4,5,6,7,8,9URVENN VYAS BIO-HY CORPORATION INDIA91-9376128018biohycorporation@yahoo.co.in I/W/D H/D/OD. V. JOLLY CEO JOLLY TECHNOCRATS INDIA91-112692310491-1126833795jollytec@.in I H2,4,5,6,8/E3R/HOME/H/E/D/ODR. R.K. SRIVASTAVA INDIA91-0115576880491-51661135rajen_sri@ O/CONSUType 商業型態 I: Importer E: Exporter M: Manufacturer W/D: Wholesaler/DistributorA: Agent G:Government Mail: Mail Order C: Chain StoresProduct 產品 Rehabilitation ProductsR1 Wheel Chair R2 ScootersR3 Walking Aid R4 Bath Room Safety AidR5 Wheel Chair/Scooter Part & AccessoriesHome Healthcare ProductsHome1 Home Care Bed Home2 Air Bed & Mattresses/ PumpHome3 Massage Products Home4 Computerized Bidet ShowerHome5 Medical & Health Supports Home6 DiapersHome7 Thermometers Home8 Weight ScalesHome9 Body Fat Monitors Home10 Body Care ProductsHome11 Ice Bag/Heating Pad Home12 Sphygmomanometer/ Stethoscopes Home13 First Aid Kit/AccessoriesHospital Equipment / Products & Medical InstrumentsH1 Hospital Bed H2 Surgical Room ProductsH3 Uric Acid Monitor H4 Respiratory ProductsH5 Sterilizers H6 Suction UnitsH7 Laboratory Equipment H8 Emergency/Ambulance SupplyH9 Medical Analytic Instruments H10 Accessories for hospital useElectronic Medical EquipmentE1 Electrocardiography E2 Ultrasonic NebulizerE3 Electro Surgical Unit E4 T.E.N.S/E.M.S. UnitsE5 Erection Section E6 EEGE7 Ambulatory Blood pressure monitor E8 Electronic Medical Equipment Parts Disposable Medical ProductsD1 Bandage/Tapes D2 Tube/Line Set & AccessoriesD3 Needles/Syringes D4 Disposable MachineryD5 Resuscitator D6 Sterilization PouchesD7 Patient’s Identification Bracelets D8 Vacuum SuctionD9 Gloves/Mask/Surgical DressingOther RelatedO1 Dental Operating Table O2 X-Ray EquipmentO3 Dental Unit O4 CastO5 Orthopedic Surgery Implant O6 Functional BracesO7 Clavicle Splints O8 Abdominal BeltsO9 Dental Disposable Products O10 Sports MedicineO11 Bio-Tech ProductsTitle 職稱 President-PR Vice President-VP Chairman-CH Vice Chairman-VC Manager-MAAssistant Manager-AM Marketing Manager-MM Purchasing Manager-GM Director-DI Section Director-SD Owner-OW Supervice-SVIG MEDIA CO., LTD.11th Floor,495,Chung Cheng Road,Xindian City,Taipei County,Taiwantel:886-2-2218-2068fax:886-2-2218-5866URL:URL:URL:。
美国康本简介
美国康本简介美国康本成立于1991年，总部位于美国，是一家过敏性皮肤疾病和问题皮肤治疗修复非药物脱敏专业机构，主要从事功能性保健品的研发、生产和销售，目前主要生产、销售葡萄籽OPC（前花青素）系列复合产品，非药物抗过敏，自然草本植物精华产品，适用于改善过敏性疾病，包括皮肤过敏、过敏性皮炎、荨麻疹、激素依赖性皮炎和过敏性鼻炎、过敏性哮喘等病症，同时适应于红血丝、粉刺、痘痘、色斑等问题皮肤的治疗修复。
美国康本（C.B.H.INT.INC.）是由美国多位著名生物学科学家、多位药品学植物学博士联合创立的专业科技生物公司，公司致力于天然草本植物生物活性提取，注重功能性保健品的研发、生产和销售，即是通过天然草本植物活性成分作用的研究，通过多种天然草本最佳配方分析实验，制造出针对人体某种疾病或需求的特殊保健食品。
采用自然草本植物精华保健产品，活化细胞以增强机体免疫力所产生的天然抗体对抗疾病，避免药物的滥用，使人体免疫系统功能发挥正常，增强免疫力并提高自我修复能力。
葡氏葡萄多酚OPC神奇功效得到发现以后，美国医学界和药学研究人员发现，最佳抗氧化剂来源存在于葡萄种子中的一种Oligomeric proanthocyanidins ，又称为OPC葡萄籽，多酚类抗氧化物质，由天然草本植物生物活性提取的葡萄籽OPC（前花青素）系列复合产品具有强大的抗敏脱敏效果。
美国康本把握国际生物工程领域的最新基础理论突破，敏锐捕捉国际保健品市场的方向性元素，对国际第四代保健品OPC（前花青素）进行研究，研发生产出天然草本植物生物活性提取的葡萄籽OPC（前花青素）系列复合健康产品，一时间风靡欧美各国，成为国际OPC领域著名的制造商，采用国际一流葡萄籽OPC提纯工艺，经过38道高科技生物工艺制取而成，以Dr.jack Masquelier发明的专利萃取法保证植物提取物质量标准化，系列产品复合现代植物提取物500多种，比单方产品功效提高50倍以上，脱敏功效更优越更高效，实现对近千种过敏源脱敏。
新核心综合学术英语教程第二册Unit6解析
the Healthpartners Research Foundation
• HealthPartners is an integrated, nonprofit health care provider located in Bloomington, Minnesota offering care, coverage, research and education to its members, patients and the community. HealthPartners was founded in 1957 as Group Health, a consumergoverned nonprofit health plan with a board of directors made up of its own members and patients. In 1992, Group Health merged with MedCenters Health Plan, and together they formed HealthPartners. In late 2012 it was announced that HealthPartners would merge with Park Nicollet Health Services of St. Louis Park on January 1, 2013 following federal approval
— Samuel Johnson • The function of education, therefore, is to teach one to think
intensively and to think critically. But education which stops with efficiency may prove the greatest menace to society. The most dangerous criminal may be the man gifted with reason, but with no morals… We must remember that intelligence is not enough. Intelligence plus character—that is the goal of true education.
AUAguideline
Gui d el i n e on the Management of Beni g n Prostati c Hyperpl a si a (BPH)Panel membersClaus G. Roehrborn, M.D., Co-ChairJohn D. McConnell, M.D., Co-ChairMichael J. Barry, M.D.Elie Benaim, M.D.Reginald C. Bruskewitz, M.D.Michael L. Blute, M.D.H. Logan Holtgrewe, M.D.Steven A. Kaplan, M.D.John L. Lange, M.D.Franklin C. Lowe, M.D.Richard G. Roberts, M.D.Barry S. Stein, M.D.Consultants and StaffHanan Bell, Ph.D.Diann Glickman, Pharm.D.Patrick FlorerIn November 2005, Boehringer Ingelheim and the U.S. Food and DrugAdministration notified healthcare professionals of revisions to PRE-CAUTIONS and ADVERSE REACTIONS sections of the prescribinginformation for Flomax (tamsulosin HCI), indicated for the treatment ofthe signs and symptoms of BPH. A surgical condition termedIntraoperative Floppy Iris Syndrome (IFIS) has been observed duringphacoemulsification cataract surgery in some patients treated withalpha-1 blockers including Flomax. Most of these reports were inpatients taking the alpha-1 blocker when IFIS occurred, but in somecases alpha-1 blocker had been stopped prior to surgery.Change Notice: Any information related to Prostate-Specific Antigen (PSA)in the following guideline may have been revised in the AmericanUrological Association's (AUA) PSA Best Practice Statement: 2009Update.In the case of any discrepency in recommendations betweenguidelines pertaining to PSA, please refer to the AUA's PSA BestPractice Statement: 2009 Update for the latest AUA recommendationregarding PSA testing.AUA Guideline on the Management of Benign Prostatic Hyperplasia: PREFACEIn 1994, under the auspices of the United States Department of Health and Human Services Agency for Health Care Policy and Research (AHCPR; now known as the Agency for Healthcare Research and Quality), the Benign Prostatic Hyperplasia Guideline Panel published evidence-based guidelines for the diagnosis and treatment of benign prostatic hyperplasia (BPH)1.Subsequently, the AHCPR reorganized; updating the previously published guidelines was no longer an objective of the Agency. Given the importance of BPH to urologists and to their patients, the American Urological Association (AUA) Practice Guidelines Committee elected to update the AHCPR document through a similar, multidisciplinary, evidence-based approach. A new panel, the AUA BPH Guideline Update Panel (the Panel) was appointed.During its initial discussions, the Panel used a consensus approach to determine if the basic framework of the 1994 AHCPR guideline was still appropriate. Except for the status of three tests in the initial evaluation of patients—serum creatinine, prostate-specific antigen, and urine cytology measurements—the use of supplementary validated symptom assessment instruments and discussion of treatment options with the patient before pressure-flow testing, the Panel believed there was no new body of evidence to suggest that the previously published diagnosis (evaluation) decision diagram be altered. Moreover, the AUA Panel felt that the fundamental approach to treatment selection—informed patient decision making—should remain a standard.The landscape of BPH treatment options had changed significantly since 1994. New forms of medical and minimally invasive treatments had been approved by the Food and Drug Administration (FDA) while other therapies had become obsolete. Balloon dilation of the prostate, for example was a recommended treatment option in 1994, and essentially a nonexistentprocedure in 2001. More importantly, the overall quality of clinical research methodologies and the validity of outcomes data had improved substantially. Randomized, controlled trials, the gold standard of treatment evaluation, were rare in the 1994 analysis, but had been published in significant numbers since. For these reasons, the Panel focused its energies on revisiting the evidence-based treatment recommendations but not the recommendations for the diagnosis of BPH.Chapter 1: Diagnosis and Treatment Recommendationsc tion 1-1 Introduandterminology 1-2 DefinitionsMethodology 1-3 Diagnostic Evaluation of benign prostatic hyperplasia 1-5 Evaluation 1-8 InitialSymptom Assessment 1-101-12c TestsOptionalDiagnostiInitial management and discussion of treatment options with the patient 1-14 Management of Patients With Bothersome Moderate to SevereBother1-14 WithoutSymptomsManagement of Patient with Bothersome Moderate to1-14 SymptomsSevereOptional Diagnostic Test for Patients Who Choose InvasiveTherapy 1-171-20c ommendationsReTreatment1-21Therapiesc ommendedRe1-21Waitingc hfulWat1-21TreatmentMedic altherapy1-22c bloc kerAlpha-adrenergiinhibitor1-23therapy5Alpha-reduc tase1-25therapyCombinationTherapies 1-26 MinimallyInvasiveThermal-basedtherapies 1-271-30ablationTransurethralneedleStents 1-31Surgery 1-32Transurethral resection of the prostate 1-33Transurethral electrovaporization of the prostate 1-34theprostate1-34ofc isionTransurethralinLaser therapy 1-351-37c tomyprostateOpen1-38 TherapiesEmergingRec ommended 1-40NotBalloonDilation:Therapies for patients with Uncommon or SeriousBPH 1-40ofComplic ationsSummary 1-42 Appendix 1Chapter 2: Methodologyc tion 2-1 IntroduDefining the topics, the literature search and data extraction 2-3c s 2-3TopiDefiningthec h 2-5SearLiteratureThec tion 2-5 DataExtraCombination 2-6 Evidenc eDeveloping re c ommendations 2-11 Limitations 2-13Reading the out c omes tables 2-16 Appendix 2Chapter 3: Results of the Treatment Outcomes AnalysesIntrodu c tion 3-1 Types of treatment out c omes 3-1 Effi c a c y Out c omes 3-2 Symptom Scores 3-2Validated symptom s c ores 3-2 Nonvalidated symptom s c ores 3-3 Custom-made symptom s c ores 3-3 Modified symptom s c ores 3-3 Peak Urinary Flow Rate 3-4 Quality-of-life S c oring Instruments 3-5 Effi c a c y Out c omes Not Analyzed 3-6 Postvoid residual urine 3-6 Invasive pressure-flow studies 3-7 Prostate volume 3-7 Serum prostate-spe c ifi c antigen 3-10 Adverse Events Out c omes 3-11 Types of treatment interventions 3-11Wat c hful Waiting 3-12 Medi c al Therapies 3-13 Minimally Invasive Therapies 3-14 Surgi c al Therapies 3-15 Out c omes Analyzed 3-15 Effi c a c y out c omes-results of analyses 3-17 Medi c al Therapies 3-18 AUA Symptom Index 3-18 Alpha blo c kers 3-18 5 Alpha-redu c tase inhibitors 3-20 Combination therapy 3-21 Peak Urinary Flow Rate 3-23 BPH Impa c t Index 3-25 Disease Specific Quality of Life Question3-26 Minimally Invasive Therapies 3-27 AUA Symptom Index 3-28 Peak Urinary Flow Rate 3-30 BPH Impa c t Index 3-31 Disease Specific Quality of Life Question3-31 Surgi c al Therapies 3-32 AUA Symptom Index 3-33 Peak Urinary Flow Rate 3-34 Disease Specific Quality of Life Question3-35Comparison of Efficacy Outcomes by Treatment Intervention 3-36 Adverse events outcomes-results of analyses 3-39Mortality 3-41 PerioperativeTherapies3-43 Medic alAsthenia 3-43Dizziness 3-45c he 3-47 HeadaHypotension3-483-49 Asymptomatic hypotension3-50c hypotensionSymptomati3-51hypotensionSymptomatic posturalc ope 3-52 SynCongestion 3-54 Respiratory/NasalEvents3-55AdverseRelatedSexually3-55c tiondysfunErec tilec tion 3-60dysfunEjac ulatoryproblems 3-62 LibidoOther 3-59events 3-59adverseCardiovasc ular3-60eventsBreastadverseShort-term Adverse Events Reported With Minimally InvasiveTherapies 3-61 AndInvasive3-61c ationsCompliIntraoperativeHematuria 3-623-64 Transfusionc tions3-66c tInfeInfec tions/UrinaryTra3-68SymptomsIrritativeVoidingUrinaryRetention 3-71c uteALong-term Adverse Events Reported With Minimally InvasiveTherapies 3-74 AndInvasivec ontinen3-74c eInUrinaryc edures 3-76Proc ondarySec ture/UrethralStri3-79c tureContrac kBladderNe3-81c tionSexualDysfunAppendix 3Chapter 4: Research and Future DirectionsIntroduc tion 4-1pathophysiology4-2 andEtiologyandepidemiology 4-3 historyNaturalmanagement 4-4 initialDiagnosisandc Interventions 4-4Therapeutic s 4-5Ec onomic ationissues 4-6 publiandReportingAppendix 4。
博士复试英文PPT
3. PTBP1 enhances exon11a skipping of Mena premRNA in lung cancer cells
Results
1. PTBP1 is highly expressed in lung adenocarcinoma (LUAD) tissues and 95-D cells and upregulation of PTBP1 is associated with EMT progress
2. PTBP1 promotes migration and invasion of lung cancer cells
Master Research
PTBP1 enhances exon11a skipping in Mena premRNA to promote migration and invasion in lung
carcinoma cells
Background Objectives Technology Methods Results Conclusions
5. PTBP1-mediated migration and invasion of 95-D cells are partially dependent on MenaINV
Results
2.1. Overexpressed PTBP1 promotes levels of EMT-related proteins in lung cancer cells
Technology Methods
Results
1. PTBP1 is highly expressed in lung adenocarcinoma (LUAD) tissues and 95-D cells and upregulation of PTBP1 is associated with EMT progress
北京百世登生物医学科技有限公司版权归北京百世登生物医学科技有限公司
WJG作者手册第1版2008-06-10温馨提示:（1）创建账号时First Author都需要注册账号;（2）E-mail地址必须是经常使用且能够与WJG编辑部保持联系的E-mail地址;（3）作者在注册完毕之后注册邮箱没有收到WJG Online邮件;（4）修改用户名、密码及账号信息，首先用刚刚创建的账号名及密码登录. 在屏幕右上角有一个“Edit My Account” 按钮，点击后即可开始修改自己的账号信息;（4）遗忘密码, 假如您忘记了自己的密码，在登录界面右侧有“I have forgotten my password”，将自己创建账号时的E-mail（用户名）输入空白框，点击“Request a New Password”，系统即刻发送一封邮件到您的信箱，告诉您的用户名及密码. 如果有其他问题，请E-mail发至submission@，或致电0086-10-85381892温馨提示: (1) 国内作者在Invoice Address(发票寄送地址栏)填写中文地址；(2) 作者在点Save/Continue时可能会出现”Error Occur”字样, 请重新检查题名及摘要内容有无特殊字符，系统屏蔽特殊字符, 建议改为英文叙述; 检查关键词的字数, 不要超过5个单词.温馨提示：要返回上一界面, 请不要直接点击Internet上的后退键, 点击：Return to the first submission.温馨提示：(1)作者在此页面需要等待数分钟, 请耐心等待一会, 系统正在提交稿件, 请不要返回电脑页面, 一旦上传文件成功后，出现的窗口会告诉上传文件的详细信息; (2)WJG系英文刊，提交的文件应全是英文，文档内容（包括文件名）不要出现中文，否则可能会无法正确上传或显示；（3）文档大小不要超过5MB，否则无法上传，如果文档过大，请转换成pdf格式然后再上传.温馨提示：（1）作者投稿完成以后返回”Author Area”看不到相关的稿件状态. 只有在当日或次日编辑部检查完作者稿件完整性以后, Correspondence Author(通讯作者) 与First Author(第一作者收到自动回执，请不要在投稿后重复投稿；（2）作者无法完成在线投稿, E-mail submission@递交修改稿如果您收到E-mail告知您的稿件需要修改后才能接受，请Manuscript Central示完成修改过程. 进入Author Center 后，查看“Manuscripts with Decisions”这一栏，点击后可以看到稿件的详细信息.界面底部，Status栏目下可以查看WJG编辑部发过来的退修信及专家审稿意见，在Action修改您的稿件.步骤2 当編务正在处理新提交的稿件时，作者界面见到的为稿件将送审（Manuscript being sent out for reviewing）.步骤4 当文章被审回后，在作者的账户下可见到文章已经审回（Manuscript revised步骤5 当审稿意见审回时，编辑部开完定稿会，文章有三个结果：拟接受、退稿和修后再审步骤2作者修改后的文章通过邮件发给科学编辑，科学编辑核对没问题后，作者所查到的是文章已经修回（Manuscript revised）.步骤4 科学编辑部主任将交了稿费的文章送给语言编辑，进行语言润色和修饰，正在编辑（Manuscript to be edited）.步骤6 科学编辑部主任，将语言编辑编回的稿件交给电子编辑或科学编辑，制作，排版，文的信息为待排版印刷（Manuscript to be typeset）.步骤8 责任科学编辑将电子编辑组完版后的文章发给作者校对，作者信息区显示的是version to be read by authors）.步骤9 电子编辑将胶片送到印刷厂，开始印刷，作者可见到印刷版出版（Publishing步骤11編务将给作者寄送书时，作者区可见到该篇文章的具体信息，即所在的卷，期，起始页码和网上链接地址.。
精准医疗计划
精准医疗计划杨晓月;陈枢青【摘要】精准医疗是指利用个人基因组信息、疾病体细胞突变信息等,进行的疾病精准诊断和依赖靶向药物等的精准治疗技术.在精准医疗项目中需对患者基因进行测序,了解疾病产生的生物分子机理,运用先进的仪器设备对患者进行精准地检查,并通过手机等移动设备提供实时生理信息,找到治疗靶点,建立疾病知识网络系统.针对患者个人的基因信息、电子健康记录中的实验数据、社会和环境数据等因素,再结合临床生理学指标,医生将为患者个体的需求确定诊断、预后和治疗的策略.本文就精准医疗的发展历程、实施流程、应用价值及未来发展需要注意的问题进行了阐述.【期刊名称】《中国生化药物杂志》【年(卷),期】2016(000)007【总页数】4页(P8-11)【关键词】精准医疗;基因组测序;靶点【作者】杨晓月;陈枢青【作者单位】浙江大学药学院精准医学与生物技术药物研究室,浙江杭州310058;浙江大学药学院精准医学与生物技术药物研究室,浙江杭州310058【正文语种】中文【中图分类】R914精准医疗(precision medicine)是建立在对人、病、药物深度认识基础上，采取的高水平医疗技术。
相比于个体化医疗，其更重视“病”的深度特征和“药”的高度精准性。
随着现代高通量测序技术、大数据和人类计算机科学技术的发展，每一天都有无数信息数据涌入人们生活(如人类基因组计划)，数据的背后蕴藏着丰富的生物学意义。
大量的基因测序数据让人们初步了解到一些疾病的发生原因，结合新兴的组学技术(如基因组学，蛋白质组学和微生物组学等)和医疗前沿技术对从患者身上获得的样本采用生物标志物进行分析和鉴定，观测到了大量与疾病相关的分子生物学特征，例如在肿瘤领域已经找到了肿瘤相关的治疗靶点PD-1等，针对特异性靶点进行疾病治疗，给肿瘤治愈带来了希望。
随着测序技术的发展，人们对疾病的深度解读，以及对未来医疗的规划，精准医疗计划应运而生。
目前，精准医疗计划已经在美国、中国、挪威、英国等国家有了初步的规划和试点研究。
辅助肥皂和脂肪吸收器泡沫类产品说明书
UnitedHealthcare PharmacyClinical Pharmacy ProgramsProgram Number 2023 P 1114-12Program Prior Authorization/NotificationMedication Includes both brand and generic versions and all formulations ofthe listed products unless otherwise noted: Weight Loss –phentermine (all brand products including Adipex-P and Lomaira),benzphetamine, Contrave (naltrexone HCl and bupropion HCl,diethylpropion, Imcivree (setmelanotide), phendimetrazine, orlistat(Xenical), Qsymia (phentermine and topiramate extended-release),Saxenda (liraglutide), and Wegovy (semaglutide)P&T Approval Date 1/08, 1/2010, 1/2011, 1/2012, 11/2012, 11/2013, 11/2014, 7/2015,9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 4/2021, 9/2021, 9/2022,2/2023Effective Date 5/1/2023;Oxford: 5/1/20231.Background:This is an optional program that is put in place for clients or businesses that have elected to cover weight loss products with Prior Authorization/Notification. It is also designed to meet regulatory requirements for coverage of weight loss medications in California, Maryland, New Mexico and New York.Classification BMI(kg/m2)Underweight< 18.50Normal range 18.50 - 24.99Overweight ≥ 25.00Obese ≥ 30.00Obese class I 30.00 - 34.99Obese class II 35.00 - 39.99Obese class III ≥ 40.00aa State mandates may apply. Any federal regulatory requirements and the member specificbenefit plan coverage may also impact coverage criteria. Other policies and utilizationmanagement programs may apply.3.Additional Clinical Rules:•Supply limits may be in place.4.References:1. American Association of Clinical Endocrinologists and American College ofEndocrinology Comprehensive Clinical Practice Guidelines for Medical Care ofPatients with Obesity. Endocr Pract. 2016;22(Suppl 3).2. National Institutes of Health, National Heart, Lung, and Blood Institute, and NorthAmerican Association for the Study of Obesity. The Practical Guide: Identification,Evaluation, and Treatment of Overweight and Obesity in Adults. 2000.3. American Gastroenterological Association medical position statement on obesity.Gastroenterology 2002 Sep;123(3):879-81.4. Bray, GA, Ryan, DH. Medical Therapy for the Patient with Obesity. Circulation.2012;125:1695-1703.5. Barlow, SE. Expert Committee Recommendations Regarding the Prevention, Assessment,and Treatment of Child and Adolescent Overweight and Obesity: Summary Report.Pediatrics 2007.6. Benzphetamine [package insert]. Laurelton, NY: Epic Pharma, LLC; January 2021.7. Diethylpropion [package insert]. Philadelphia, PA: Lannett Company, Inc.; December2019.8. Phendimetrazine Slow-Release Capsules [package insert]. Princeton, NJ: Sandoz Inc.;November 2018.9. Adipex-P [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; s ;March2020. 10. X enical [package insert]. South San Franciso, CA : Roche Pharmaceuticals;September 2020.10. Qsymia [package insert]. Moutain View, CA. Vivus, Inc ; June 2022.11 Contrave [package insert]. Brentwood, TN: Currax Pharmaceuticals, LLC; November2021.12. Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk ; June 2022.13. Pharmacological Management of Obesity: An Endocrine Society Clinical PracticeGuideline. The Journal of Clinical Endocrinology & Metabolism 2015 100:2, 342-36214. AHA/ACC/TOS Prevention Guideline: 2013 AHA/ACC/TOS Guideline for theManagement of Overweight and Obesity in Adults: A Report to the American College ofCardiology/American Health Association Task Force on Practice Guidelines and TheObesity Society. Circulation. 2014; 129:S102-13815. World Health Organization. (2006). Global Database on Body Mass Index. Retrievedfrom https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index16. Lomaira [package insert]. Newtown, PA: KVK-Tech, Inc. December 2018.17. Imcivree [package insert]. Boston, MA: Rhythm Pharmaceuticals, Inc; June 2022.18. Wegovy [package insert]. Plainsboro, NJ: Novo Nordisk; December 2022.Program Weight LossChange ControlDate Change11/2013 Reformatted to standard and updated references. Clarified risk factorsrequired in addition to BMI of 27-29. Removed criteria that coveragewould not be provided if used in combination with other weight lossagents. Shortened initial authorization for sympathomimetics to 3months based on PI recommendations for short-term use. Addedreauthorization criteria for 6 months, changed initial authorizationperiod of Xenical from 4 months to 3 months, and shortenedreauthorization of Belviq and Xenical to 12 months for alignment withOptumRx.11/2014 Added Contrave to guideline.7/2015 Added Saxenda to guideline.9/2016 Annual Review. Added Belviq XR to guideline. Revised authorizationperiod for Xenical. Removed ASO from title- program will remain asASO option.9/2017 Annual Review. Added Lomaira. Updated references. Revisedweightloss percentage for Saxenda per PI.9/2018 Annual Review. Updated references. .9/2019 Annual Review. Revised background section. Revised list ofmodifications of weight related comorbidity.9/2020 Annual review. Updated references. Removed Belviq/Belviq XR.4/2021 Added Imcivree as in scope. Added Imcivree criteria. Updatedreferences. Formatting changes.9/2021 Added Wegovy to criteria. Updated Saxenda criteria to allow forcoverage for 12 years and older. Updated Qsymia weight loss goal togreater than 3 percent per label and changed initial authorization to 4months. Updated references.9/2022 Added background note that this program is intended to meet regulatoryrequirements for coverage of weight loss medications in California,Maryland, New Mexico and New York. This program is replacingpolicy P 1172-8. Changed Qsymia age requirement to 12 or older due tonew pediatric labeling. Updated Imcivree to include new FDAapproved indication for Bardet-Biedl syndrome. Updated references. 2/2023 Updated Wegovy criteria to include pediatric patients based on newlabeling. Added state mandate language.。
曼哈顿医学计划：世界上最富有医生能拯救医疗体系吗
曼哈顿医学计划：世界上最富有医生能拯救医疗体系吗作者：暂无来源：《东方企业家》 2014年第10期编译／凌雯静这项靠无数数据集合而成的惊人成就，市值惊人，可达到13 亿美元。
毫无疑问，其造价也十分惊人，不过大多数都是陈颂雄自掏腰包建成的。
洛杉矶，一个常规的完美夏日，人类有史以来最富有的医生陈颂雄正在他的“秘密基地”里虚席以待，会见一个他志趣相投的人。
这个人正是T. 丹尼·斯坦福，他从向信用不佳者兜售万事达卡高利贷，获取了28 亿美元的财富。
不过现在，他散去自己的大部分财富，给到儿童慈善基金会和医院——他是来看未来医学究竟会发展成个什么样的。
陈颂雄今年62 岁，这场展示他有很多要展现。
起初，他穿梭于一个未来医院模型中：其中有一个眼罩，能够测量病人的心跳，体温和血压；还有一个三英尺的白色立方体，叫做HBox, 将所有电子设备连向电脑网络。
他在电脑屏幕上展示了一个暗室：一个控制中心，几个医生就能遥控几百个病人，即便病人在家也可以。
最后陈颂雄打开了几个电脑程序让大家知道，这种方式根据最新的科学月刊文章显示，是能够达到最佳医疗效果的。
这项靠无数数据集合而成的惊人成就，市值惊人，可达到13 亿美元。
毫无疑问，其造价也十分惊人，不过大多数都是陈颂雄自掏腰包建成的。
斯坦福穿着不修边幅的蓝色T 恤和配套裤子，这样炫目的展示让人惊讶不已，让他看上去更凌乱了。
“我觉得这就是我们需要的东西，”斯坦福说，“我还有个医疗集团，我们可以在四十个医院和150 个诊所试水，但是花费肯定是惊人的，还有，这些组织之间的联系也是主要需要解决的问题。
”陈颂雄则更加直击主题，他说：“医院和医院间的确没有组织起来，也根本没有资金和技术去组织，所以造成了眼下的联系混乱。
老实说，政府应当要负责任。
”由于奥巴马医改的失败，陈颂雄此举看上去更加“显得正确”，斯坦福对他所说心悦诚服，他们握了手，并且急切地签署了共同将此项技术用于凤凰城儿童医院的意向。
Dementia A Public Health Priority
Dementia worldvarious estimates about the number of people with dementia in China
World Alzheimer Report 2010: 5.4 million 2030: 11.7 million 2050: 22.0 million Other studies suggest 10 million now
About Alzheimer’s Disease International (ADI)
• Established 1984 • The umbrella organisation of Alzheimer associations around the world • 79 member associations Aims to help establish and strengthen Alzheimer associations throughout the world, and to raise global awareness about Alzheimer's disease and all other causes of dementia
• 30 research groups in 20 countries in Latin America, the Caribbean, India, Russia, China and south east Asia, Lebanon
/1066
World Alzheimer’s Month
Why dementia is a public health issue?
1. The world's population is ageing
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
卓信医学网络讲坛剧本大家好，欢迎参与2010年首场卓信医学网络讲坛。
我是赖强，这2位是艾美仕市场调研有限公司（IMS Health）的徐敏仪女士和宓子厚博士。
今天很高兴邀请到IMS Health的2位资深咨询专家,与我们一起探讨医改推出一年后, 对市场的回顾及展望. 今天的在线访谈会涵盖4个话题, 分别是: 回顾医改一周年出台的政策; MAT2010年4月中国医院用药市场数据解析; 跨国药企的在华市场策略变革; 未来中国医院用药市场的变化. 徐女士会与大家分享第一个话题. 宓博士将稍后与各位探讨余下的三个话题. 首先有请徐女士…在就职于艾美仕市场调研公司的过程中，Mandy在中国医药市场从事咨询服务超过15年。
Mandy擅长于为医疗行业的客户就如何提升商业策略和如何加速在新兴市场中的增长机会提供建议。
今天我们要探讨的是中国的医疗改革——回顾医改一周年出台的政策以及行业应对措施。
你好，Mandy。
你好，赖先生。
2009年初，中国政府发布了改革医疗制度的计划，目的是到2011年要让中国13亿人口的90%都能享受到医疗保险。
Mandy，这是一项非常巨大的挑战。
请您谈谈中国医疗改革的背景资料，以便我们全面地看待这一问题。
当然可以，尽管中国保持着强劲的经济发展势头, 但个人医疗自费比例为55%, 排名位于各医药新兴市场前列. 在中国经济发展的20年中，事实上中国的医疗制度并没有跟上经济增长的脚步，所以许多医院病人过满. 可以说, 医疗保健资源非常有限. 每1000人只享有3.8名专业医疗人员的服务和3.1个床位; 就医等候时间长–挂号平均要25分钟, 等候89分钟, 而医生对病人的直接诊疗时间仅6分钟. 农村地区资源分配严重不足 -占总人口54%的农村人口仅享有22.5%的医疗花费. 很多设备无法用到服务大众的目的中来.中国医疗保健体制最根本的问题在哪里?中国医疗保健体制的最根本的挑战在于可及性和人们较差的支付能力. 刚才我已谈了可及性的问题. 现在我们来看下人们的支付能力.现今, 医疗成本不断增加–是1990年自费医疗支出的18倍; 医疗自费比例高–医疗支出的45%由个人承担; 医疗费用负担不起-高达35%的城市居民和43%的农村家庭表示医疗费用难以承担.总结来看, 中国医疗保健体制的根本问题在于:医疗保健资源不足; 资源分配不公不平衡; 医疗保健体系效率低不平衡; 医疗保险覆盖不足; 医院依赖药物收入运营.此次改革的目的就是为了解决先前体制中存在的问题？从某种意义上来说是这样的。
中国的发展十分迅猛，人口老年化趋势日益明显，许多疾病类型也在不断变化。
城市化进程也十分迅速，因为大量的人群从农村地区迁移出来，并在城市参加工作。
生活方式改变的同时，很多慢性病也突显出来，例如糖尿病和高血压。
随着某些疾病日益普遍和突出，政府需要具有针对这些病人群体进行治疗的能力，所以政府需要实现基础设施建设，以适应中国人口和流行病趋势的变化。
在三年之内将有1250亿元投入到这个领域中来。
这些资金将用于哪些措施？约有一半的资金将被用于提供广大群众的医疗保险，因为政府计划到2020年每人都能享有不同的保险，到2011年医保系统将能覆盖90%的人群, 增加3个医保方案的保额和报销比例.另一部分是关于提供基本医疗保健服务，以保证基础设施建设，尤其是基本医疗设施，例如开发基本医疗保健服务网络; 建设2,000家县级医院, 3,700家城镇社区卫生中心和30,000家社区卫生站剩余的资金将用于公立医院改革, 合理的公共医疗服务等; 旨在通过开展公立医院改革试点, 以期逐渐排除药品加价; 实现医院监管与运营分离. 提供农村和城市平等共享公共医疗服务.改善专科医疗机构基础设施, 如精神卫生中心, 妇科及儿科诊疗机构这些举措中的首要工作重点是什么呢?首要工作重点是, 至2011年, 将医疗保险覆盖范围扩大到全部人口的90%. 刚才我提到, 现行的保险体制有3种, 分别是: UEBMI (城镇职工BMI) , 于1998年执行, 提供门诊和住院的最好福利待遇; 还有URBMI (城镇居民BMI) - 2007年执行, 主要覆盖了住院治疗, 但门诊治疗花费覆盖很有限; 第三种是NRCMS (新农村合作医疗方案) - 2003年执行, 主要覆盖重大疾病.从这张图表中, 显而易见, 2005年时, 由于(城镇居民BMI) 还未实施, 城镇人口的受保率仅为23%; 农村人口为20%; 到2011年, 对城镇人口来说, 城镇职工和城镇居民BMI 的共同作用下, 全体受保人口将达到90%; 同样的, 新农村合作医疗方案也将覆盖90%的农村人口. 这是一项非常雄心勃勃的计划!我了解到有另一个由此次医改带来的非常重要的发展举措—那就是国家医保目录（NRDL）。
您能详细谈谈吗？好的. 国家医保目录 (NRDL) 在2009年也扩大了覆盖范围, 以期进一步增强人们的支付能力并减轻药价对人们的负担. 我们先来看一下国家医保目录(NRDL)选择标准, 分别是: 临床必需; 安全性和疗效; 合理定价; 使用方便; 市场供给保证. 原则上说, 国家医保目录(NRDL) 每2年根据国家人力资源与社会保障部的法规修改一次. 事实上, 国家医保目录(NRDL)仅在2000, 2004和2009年修改过. 如图所示, 2004年的NRDL中, List A总共有450种药品, 而List B总共有1,400种, 其中西药占了712种; 而到了2009年目录修改以后, List A有503种药品; List B药品数目上升到了1,624中, 其中西药占有791种.刚才你有提到医疗保健资源不平衡使用的问题, 请问计划如何解决这一问题呢?为解决医疗保健资源不平衡使用的问题, 一级基本医疗机构将在城镇和农村建立, 医疗保健供给体系将不断发展.现状是, 我们虽然有3级医疗机构, 但是这些资源并没有合理使用. 几乎所有类型的病人, 不管其病情的严重程度如何, 都蜂拥而至三级医疗保健机构, 使三级机构的就诊病人数目多到不成比例; 而二级和一级/基本医疗保健机构却未被充分利用, 造成资源浪费.为解决这一问题, 通过改革希望将来能做到三个级别的医疗保健机构都得到充分合理地利用. 如: 一级基本医疗保健机构主要收诊小病或常见疾病的门诊病人和疾病预防. 而二级机构负责提供急诊及综合医院服务; 三级机构主要为专科医院, 专注于疑难杂症及科研. 根据病情严重程度, 病人可以选择在各级医院之间转诊.这真是令人振奋的消息. 请问这一系列改革举措, 对在华药企会产生什么样的影响呢?从短期来看, 国家医保目录(NDRL)的执行及定价改革将产生最大的影响. 其中积极因素包括: 国家医保目录(NRDL)/省级医保目录(PRDL)的执行, 目前未参加医保人群会增加其医保覆盖, 增强的保险福利, 高价药品的议价机制等. 同时也会伴有一些不利的因素, 如定价改革, 公立医院改革及更严格的保险费用遏制管理. 其中最引人瞩目的是基本医保目录的实行与基本医疗保健服务的发展, 这二项并称为改革的双刃剑.那么现行的运营模式在近期内会改变吗?不, 现行的运营模式在近期内不会改变. 不会改变的现状主要有: 医药公司销售模式, 大型城镇医院仍占有主要市场, 自费医疗的负担仍十分沉重,改革对药物定价有什么影响呢?改革对价格会产生较大的压力, 但是仍有协商的空间在这个转型期, 对于专利药来说, 定价应以价值为导向, 而非以成本为定价基础, 同时也需要以国际市场为参照进行定价, 在上市一些年后进行降价; 而对于专利失效的原研药来说, 价格压力下降, 原研药和仿制药的价格差距不断缩小, 但有着”以质为本”的独立定价空间. 将来, 对于仿制药来说, 初入市时可实行较高定价, 而对于专利失效的原研药, LOE后实行强制降价; 但他们都享有”以质为本”的独立定价空间. 总结来说, 改革的目标就是5年后能有统一的价格; 且价格依赖于药品的成熟度及仿制药数量.那么改革对创新产品有什么作用呢?创新产品将在改革中获利; 寻求新药上市的最佳定价将需要药物经济学研究(HEOR).复杂的改革使这个市场机遇与挑战并存.对于新品牌药来说, 由于保险人群扩大, 更多病人能获得医疗服务; 基本医疗保健机构的建立, 使人们的疾病意识不断增强, 且由于病人电子档案的实现, 将提高相关规则的遵守度. 这些都是有利因素; 同时使用DRG 和其他方式的价格审查将更严格; IMS认为, 药物经济学研究(HEOR), 为中国市场定制, 提供合理制定最佳入市价格的服务, 将变得越来越重要.对于高价创新肿瘤药/生物制剂来说, 列入国家医保目录(NRDL)是可能的, 但需要创新的协商机制; 与商业医疗保险公司合作以扩大可及性人群的机遇. 与此同时, 价格交换(折扣,价量协定等)也将带来不同程度的挑战.入基本医保目录有什么正面和负面的影响呢?对于进入基本医保目录的成熟产品, 由于药品的强制使用, 销量将大幅度提升, 而且EDL 使该药品有能力进入新的领域, 如社区卫生中心及农村地区,而这些地区以前都是跨国企业不曾进入的领域.同时EDL也会带来一定的挑战. 由于必须与发布的上限价保持一致, 就要面临大幅度降价.而且在执行上会有很大差异, 例如不同省份间的定价, 招标, 分销等. 而且即使降价, 销量的上升也不是可以保证的.那么对专利失效的原研药有什么潜在影响呢?同样, 影响也是双方面的.因为质量较好, 专利失效的原研药会有“独立定价”的机会. 而且由于受保人群扩大及更好的保险福利, 销量会增加.但是, 价格大幅下降会带来压力, 使得与仿制药的价格差距缩小;仿制药入侵也会更多.为了使结果最优化, 在华医药企业该采取哪些行动呢?这个问题应该从3个方面来看. 分别是公司层面, 投资组合以及产品线.公司组织架构需应对改革进行妥善调整, 内部资源得到协调统一, 采用适应公司进一步发展的最优化的商业模式.同时, 对投资组合, 病人市场细分, 及销售渠道都需进行重新评估.对于产品来说, 定价及入市选择, 询证需求的考量, 支付策略的制定都是十分重要的.在这些领域都必须立刻采取行动, 不论是短期还是长期.Mandy。
谢谢您和我们分享关于中国医疗体制改革的观点。
这是医疗行业的最佳时机。
也是中国百姓的绝佳时机。
下面让我们有请宓子厚博士与我们分享接下来的3个话题.宓博士目前任职于艾美仕中国咨询服务部，担任投资组合与产品策略的首席咨询顾问。
宓博士在美国和亚洲的制药和生物科技行业有超过10年的工作经验，在新产品开发，投资组合管理，业务拓展和公司规划方面都担任过领导工作。